[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
OBJECTIVE
To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC).


METHODS
Forty patients with HCC were treated with sorafenib (400 mg bid) after TACE. The efficacy was evaluated according to RECIST 1.1 criteria, and side effects were assessed by NCI CTC 3.0 criteria.


RESULTS
Among the forty cases, one case achieved complete remission (CR), seven cases achieved partial remission (PR), nineteen cases achieved stable disease (SD) and thirteen cases had progressive disease (PD). The disease control rate (DCR) was 67.5%. The overall survival time was 1 - 18 months, and 1-year survival rate was 54.0%. The major adverse events were hand-foot skin reaction, diarrhea and thrombocytopenia.


CONCLUSIONS
The combined therapy of TACE and sorafenib is effective and well tolerated for advanced HCC.
Department of Integrated Chinese and Western Medicine, Cancer Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Li-tao
LT
Xu
Zhen
Z
Chen
Jun-hua
JH
Lin
Zhen-hua
ZH
Zhou
Hao
H
Chen
Zhi-qiang
ZQ
Meng
Lu-ming
LM
Liu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D003131:Combined Modality Therapy; D003967:Diarrhea / Q000209:etiology; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D000077157:Sorafenib; D015996:Survival Rate; D013921:Thrombocytopenia / Q000209:etiology; D055815:Young Adult
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D009944:Organoplatinum Compounds; D010671:Phenylurea Compounds; D011725:Pyridines; D000077150:Oxaliplatin; D009536:Niacinamide; D004317:Doxorubicin; D000077157:Sorafenib; C027260:pirarubicin